Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Transcriptional footprints of cancer dependency shock as a computational tool for early anti-cancer drug discovery

Project description

A closer look at cancer’s survival secrets

Cancer’s survival mechanisms present a formidable obstacle in treatment. Following the inactivation of essential cancer genes, a complex interplay of signals occurs, impacting cell survival pathways. Dubbing this intricate phenomenon cancer dependency shock, which remains enigmatic in therapeutic targeting, the ERC-funded DepSHOCK project aims to address this challenge. Specifically, the research team seeks to decipher these footprints to reveal markers crucial for cancer cell survival. Using innovative computational methods and analysing unprecedented transcriptional data sets at single-cell resolution, they aim to identify therapeutic targets. The project aspires to lead the way in early anti-cancer drug discovery by providing grounded markers and insights for developing combinatorial therapies.

Objective

The oncogenic shock model has been introduced to describe the interplay between pro-survival and pro-apoptotic signals that follow an oncogene's inactivation and lead to cancer cell death.
In my recent work, I demonstrated that identifying novel cancer dependencies through systematic computational analyses of CRISPR functional genetic screens and multi-omic data is an excellent means to discover and prioritise new anti-cancer therapeutic targets. Here, I extend the oncogenic shock concept to any cancer dependency gene. I call cancer dependency shock (DepSHOCK) the signal dynamics interplay that follows the ablation of any gene essential for cancer cell survival, i.e. cancer dependency gene. Any DepSHOCK triggers the sudden inactivation of pro-survival pathways and activates death- inducing signals, with both events impacting down-streaming transcription factors, leaving a measurable gene expression footprint. My hypothesis is that each DepSHOCK footprint can be deconvoluted to infer transcriptional markers of signals that emanate from a dependency gene and drive cancer cell survival through the constitutive activity of specific biological pathways. Here I propose to investigate this hypothesis across tissues, canonical oncogenic addictions, and novel candidate cancer therapeutic targets. To this aim, I plan to establish an experimental/computational platform for the generation and the analysis of unprecedented transcriptional datasets obtained at single-cell resolution upon genetic perturbation of a rationally selected panel of cancer cell lines and therapeutically relevant dependency genes. My overarching goal will be to study the information content of the DepSHOCK footprints and their potential use as computational tools in early anti-cancer drug discovery through new statistical and machine-learning methods delivering mechanistically grounded therapeutic markers and hints for the design of combinatorial therapies.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-ERC - HORIZON ERC Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2023-COG

See all projects funded under this call

Host institution

FONDAZIONE HUMAN TECHNOPOLE
Net EU contribution
€ 1 999 455,00
Address
VIALE LEVI MONTALCINI RITA 1
20157 Milano
Italy
Region
Nord-Ovest Lombardia Milano
Activity type
Research Organisations
Links
Total cost
€ 1 999 455,00

Beneficiaries (1)